Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the neurological biomarkers market?

In recent times, there has been a swift expansion in the size of the neurological biomarkers market. It is projected to escalate from $10.7 billion in 2024 to $11.96 billion in 2025, with a compound annual growth rate (CAGR) of 11.7%. This growth during the historical period can be credited to factors such as an upsurge in neurological disorders, an aging population, needs for drug development, a rise in funding for neurological research, and the advent of personalized medicine.

What will be the neurological biomarkers market size in the future?

The size of the neurological biomarkers market is anticipated to experience swift expansion in the coming years, swelling to $19.96 billion by 2029, with a compound annual growth rate (CAGR) of 13.7%. Multiple factors contribute to this forecasted growth include the use of biomarkers for early detection, biosensors, wearable technology, worldwide health initiatives, and a patient-focused approach. Key trends anticipated during the forecast period encompass technological progress in image capturing, rapid evolution in omics technologies, the incorporation of artificial intelligence (AI), the application of real-world evidence in biomarker authentication, progress in diagnostic technologies, and partnerships between industry and research institutions.

Get your neurological biomarkers market report here!

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

What main drivers are fueling expansion in the neurological biomarkers market?

Advancements in the neurological biomarker market can be fuelled by the escalating occurrence of neurological ailments. Such health issues, which impinge on the brain, spinal cord, and the rest of the body’s neurologic circuit, include Parkinson’s disease, a neurodegenerative affliction that affects the nervous system and nerve-controlled body areas. Neurological biomarkers can facilitate early detection of Parkinson’s disease through pathological, biochemical, and genetic analysis. For example, information from the Parkinson’s Foundation, a non-profit organization in the US, revealed a surge in the diagnosis of Parkinson’s, hitting 90,000 in 2022 from an annual rate of 60,000 in 2021. Therefore, the rising incidence of neurological conditions is propelling the expansion of the neurological biomarker market.

What key areas define the segmentation of the global neurological biomarkers market?

The neurological biomarkers market covered in this report is segmented –

1) By Product: Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products

2) By Application: Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy

3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users

Subsegments:

1) By Proteomics Biomarker: Protein Biomarkers, Antibody Biomarkers

2) By Genomics Biomarker: DNA Biomarkers, RNA Biomarkers

3) By Metabolomics Biomarker: Metabolite Biomarkers, Lipid Biomarkers

4) By Imaging Biomarker: MRI Biomarkers, PET Scan Biomarkers

5) By Other Products: Neuroinflammatory Biomarkers, Neurotransmitter Biomarkers

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp

Who are the dominant players expanding their reach in the neurological biomarkers market?

Major companies operating in the neurological biomarkers market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

How are evolving market trends shaping neurological biomarkers Strategies?

Prominent firms in the neurological biomarkers market are partnering up to create new products and bolster their standing in the market. These collaborations and partnerships stimulate innovation, harness synergistic expertise, and accelerate the development and market introduction of advanced treatments by pooling resources and abilities. For example, in July 2022, NeuroSense Therapeutics Ltd., an Israeli firm specializing in the treatment of severe neurodegenerative diseases, entered a partnership with NeuraLight, another Israeli firm that develops precise and responsive biomarkers for neurological disorders. Their joint goal is to identify oculometric indicators for Amyotrophic Lateral Sclerosis (ALS) by utilizing Artificial Intelligence (AI) and Machine Learning (ML). This initiative, following NeuraLight’s $25 million Series A funding round, aims to amplify the discovery and use of ALS digital indicators in a parallel research project. This will be the first clinical trial of this partnership. The main focus of this partnership is the use of oculometric digital indicators, which could facilitate patient categorization and increase the success rate of clinical trials.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12677

Which regions are emerging as leaders in the neurological biomarkers market?

North America was the largest region in the neurological biomarkers market in 2024. The regions covered in the neurological biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Cardiac Biomarkers Testing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

Neurology Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Renal Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: